A collaboration between scientists at the Institute of Molecular and Clinical Ophthalmology Basel (IOB) and Beam Therapeutics has resulted in a new base editing therapy for Stargardt disease, the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback